{"domain":"dyne-tx.com","status":"valid","tier":"listed","authority":54,"verified":false,"title":"Dyne Therapeutics","summary":"Dyne Therapeutics, Inc. (Nasdaq: DYN) is a clinical-stage biotechnology company headquartered in Waltham, Massachusetts, developing targeted therapeutics for genetically driven neuromuscular diseases. Dyne's proprietary FORCE™ platform conjugates an antigen-binding fragment (Fab) that binds transferrin receptor 1 (TfR1) to a therapeutic payload — such as an antisense oligonucleotide (ASO), phosphorodiamidate morpholino oligomer (PMO), siRNA or biologic — to enable delivery to muscle and the cent","llms_txt":"https://www.dyne-tx.com/llms.txt","llms_full_txt":"https://www.dyne-tx.com/llms-full.txt","last_checked":"2026-10-20T22:57:31.097Z","agent_terms":null,"categories":[],"capabilities":[],"inferred_tags":[],"audience":null,"agent_uses":[],"language":null,"platform_generated":null,"agent_summary":null,"llms_txt_cached":"https://agentwebmap.com/v1/domain/dyne-tx.com/llms.txt","agentic":"documentation","section_keys":["clinical-trials","company","for-healthcare-professionals","letters-to-the-community","optional","patient-and-community","patient-stories","pipeline-and-programs","science-and-platform"],"section_partial":false,"section_indexed_at":"2026-10-21T14:09:49.225Z"}